| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Strata Oncology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $128.35M | Series A-3 | 7/28/2021 | $84.92M | $561.3M | $34.88 | Wellington Management, Cormorant Asset Management, Monashee Investment Management, Highside Capital Management, Pfizer Ventures, Merck Global Health Innovation Fund, Arboretum Ventures, Deerfield Management, Baird Capital, Renaissance Venture Capital | ||||
 | Amylyx | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $203.25M | Series C-1 | 7/20/2021 | $107.33M | $541.01M | $10.27 | Viking Global Investors, Bain Capital Life Sciences, Perceptive Advisors, Rock Springs Capital, Woodline Partners, Marshall Wace, Tybourne Capital Management, Verition Fund Management, aMoon Fund, Falcon Edge, Morningside Ventures, 683 Capital Management, Belinda Termeer, Polaris Founders Capital | ||||
 | Axtria | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $159.97M | Series E | 5/13/2021 | $100.1M | $920.88M | $9.53 | Bain Capital Tech Opportunities | ||||
 | Cerapedics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $163.58M | Series G | 6/5/2024 | $15.23M | $744.31M | $5.64 | Undisclosed Investors | ||||
 | DNAnexus | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.14B | Series I | 3/8/2022 | $200M | $616.31M | $0.61 | Blackstone Growth, Northpond Ventures, GV, Perceptive Advisors, Innovatus Capital Partners, Foresite Capital | ||||
 | Harbinger Health | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $470.04M | Series B-1 | 2/20/2025 | $289.97M | $781.26M | $6.60 | Undisclosed Investors | ||||
 | Medrobotics | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $197.87M | Series H | 1/26/2017 | $24.2M | $585.16M | $4.84 | Undisclosed Investors | ||||
 | Mindstrong Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $160.35M | Series C | 5/21/2020 | $100M | $703.91M | $8.01 | General Catalyst, ARCH Venture Partners, Foresite Capital, 8VC, Optum Ventures, What If Ventures | ||||
 | Neurelis | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $247.94M | Series D | 3/9/2021 | $114.76M | $544.18M | $3.15 | Cormorant Asset Management, Decheng Capital, LYZZ Capital, HBM Healthcare Investments, Philos & Partners SA | ||||
 | Ollin | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $431.81M | Series B | 6/24/2026 | $331.81M | $876.79M | $3.00 | TCGX, ARCH Venture Partners, Andreessen Horowitz, Blackstone, Commodore Capital, CPP Investments, RA Capital Management, Mubadala Capital, Monograph Capital, T. Rowe Price | ||||
 | Omniome | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $153.29M | Series C | 1/9/2020 | $60M | $511M | $4.17 | Madrone Capital Partners, ARCH Venture Partners, Decheng Capital, Domain Associates, Biomatics Capital Partners, Altitude Life Science Ventures, Nan Fung Life Sciences | ||||
 | Valo | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $406.25M | Series B | 3/9/2021 | $310M | $919.92M | $5.88 | PSP Investments, Flagship Pioneering, Invus Public Equities, HBM Healthcare Investments, Atinum Investment, Mirae Asset Capital, Koch Disruptive Technologies | ||||
 | Aetion | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $411.43M | Series C | 5/11/2021 | $110M | $585.67M | $13.13 | Warburg Pincus, B Capital, Foresite Capital, New Enterprise Associates, Flare Capital Partners | ||||
 | BrightInsight | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $179M | Series C+ | 1/20/2026 | $57.29M | $750M | $9.13 | -- | ||||
 | Doctor on Demand | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $239.67M | Series D | 7/8/2020 | $78.74M | $820.61M | $28.53 | General Atlantic | ||||
 | Equip | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $144.89M | Series D | 9/16/2025 | $47.89M | $863.1M | $29.89 | Kerry Washington, Pledge Ventures | ||||
 | Found Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $132.31M | Series BB | 12/16/2021 | $100M | $601.15M | $1.83 | WestCap, IVP, The Chernin Group, G9 Ventures, Able Partners, GV, Atomic, Define Ventures, Fidji Simo, Julia Cheek | ||||
 | Notable | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $126.5M | Series B | 11/3/2021 | $100M | $600.67M | $3.49 | ICONIQ Growth, Greylock Partners, F-Prime Capital, Oak HC/FT | ||||
 | RayzeBio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $795.51M | Series D | 9/13/2022 | $159.75M | $599.64M | $2.50 | Viking Global Investors, Sofinnova Investments, Wellington Management, Ally Bridge Group, Sands Capital, Laurion Capital Management, Soleus Capital | ||||
 | ReCode Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $397.77M | Series B | 9/23/2025 | $290M | $588.16M | $9.23 | Matrix Capital Management, Pfizer Ventures, EcoR1 Capital, Sanofi Ventures, Tekla Capital Management, Superstring Capital, NS Investment, OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, Osage University Partners, Bayer, Amgen, CF Foundation | ||||
 | Seaport Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $330.1M | Series B | 10/21/2024 | $226M | $725.46M | $14.92 | General Atlantic, T. Rowe Price Associates, Foresite Capital, Invus, Goldman Sachs, CPP Investments, ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures, PureTech Health | ||||
 | Sonoma Biotherapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $365.1M | Series B-1 | 3/28/2023 | $147.78M | $732.39M | $2.96 | Ally Bridge Group, ArrowMark, Avidity Partners, Casdin Capital, Deep Track Capital, Fidelity Management, Frazier Healthcare Partners, GV, Janus Henderson Investors, Mirae Asset, NS Investment, Osage University Partners, Piper Heartland Healthcare Capital, Vertex Ventures HC, 8VC, ARCH Venture Partners, Alexandria Venture Investments, JDRF T1D Fund, LifeForce Capital, Lilly Asia Ventures Biosciences, Octagon Capital, Regeneron | ||||
 | Apprentice | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $189.97M | Series C | 3/20/2023 | $151.97M | $622.45M | $12.48 | Alkeon Capital Management, Silverton Partners, Insight Partners, Pacific Western Bank, Colorcon Ventures, ICONIQ Growth | ||||
 | Expedition Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $280M | Series B | 8/5/2026 | $115M | $599.82M | $7.43 | General Atlantic, RA Capital, Vivo Capital, Novo Holdings, Sofinnova Investments, Forbion, Dawn Biopharma, Venrock, Sanofi Ventures, Logos Capital, Biotechnology Value Fund, Balyasny, Adage | ||||